2005	2006	2007	2008	20092)	20103)
in EUR millions1)
Sales	237.6	281.9	326.4	423.0	440.2	412.5
EBITDA	39.6	46.9	54.9	81.8	87.4	69.8
EBIT	25.3	31.4	38.5	55.6	61.5	42.9
Profit before tax	15.0	21.6	30.2	40.5	49.0	28.4
Net profit	10.2	16.0	15.5	25.7	31.9	19.6
Balance Sheet Total	351.0	362.1	536.7	592.0	633.5	632.3
Shareholders’ equity	164.8	179.3	225.8	253.4	269.9	307.6
Dividend in EUR
Ordinary	0.12	0.24	0.30	0.30	0.34	0.38
Preference	0.18	0.30	0.36	0.36	0.40	0.44
Staff	1,074	1,149	1,727	1,952	1,834	1,611

	2008			20092)			20103)			20113)
in EUR millions1)	Q1	Q2	Q3	Q1	Q2	Q3	Q1	Q2	Q3	Q1	Q2	Q3
Sales	105.5	105.4	112.1	119.4	119.8	122.7	115.0	112.1	115.2	106.5	106.4	99.0
EBIT	13.3	14.3	16.3	14.4	15.0	15.8	12.3	11.4	11.5	9.1	10.9	10.1
Profit before tax	9.7	10.5	12.6	11.2	12.2	12.6	10.2	10.2	2.8	6.6	8.3	5.3
Profit after tax	6.6	7.8	8.3	7.7	8.3	9.1	7.5	7.1	1.2	4.4	7.3	27.3
Balance Sheet   Total	551.1	571.4	583.7	613.5	629.7	644.5	636.9	656.1	640.5	637.9	680.8	721.9
Shareholders’   equity	227.4	231.9	246.6	264.0	264.5	269.1	297.7	308.5	300.7	308.6	307.9	339.8
Staff	1,799	1,830	1,893	2,064	2,099	2,135	1,830	1,851	1,854	1,627	1,649	1,670

¹⁾ all figures according to IFRS/IAS
²⁾ Continuing Operations after disposal of the transfusion and transplantation activities to Bio-Rad Laboratories, Inc.
³⁾ Continuing Operations after disposal of the transfusion and transplantation activities to Bio-Rad Laboratories, Inc. and the microbiological Monitoring to Merck KGaA